Tricuspid Regurgitation: Simple Clinical Risk Score For Mortality

Tricuspid regurgitation (TR) is a heart valve problem that is often underestimated, but it can seriously affect a patient’s health and survival. Although it was once considered mainly a result of left sided heart faluire, current understanding shows that TR can also cause symptoms and complications on its own. Patients may experience tiredness, breathlessness, swelling in the legs or abdomen and worsening heart failure symptoms. For clinicians, significant TR should be recognised as an important condition that may increase the risk of hospitalisation and mortality. A simple clinical risk score can help estimate prognosis by combining symptoms, heart imaging findings, blood test results and other medical conditions into one practical number. This can support earlier specialist referral, closer follow up and timely treatment decisions while helping patients better understand their condition.

Why It Matters

For many years, tricuspid regurgitation (TR) was viewed mainly as a secondary problem caused by disease on the left side of the heart. The usual approach was to treat the left-heart condition first and hope that TR would improve. However, clinical practice now shows that significant TR itself can be the main reason for symptoms such as weakness, leg or abdominal swelling, repeated heart failure admissions, and reduced daily function. When the tricuspid valve does not close properly, the right ventricle has to work harder, and blood can flow backward toward organs such as the liver and kidneys. Over time, this can contribute to organ dysfunction, frailty, and worsening heart failure. Studies have shown that moderate to severe TR is linked with a much higher risk of death over the following years, even after considering other medical conditions.

For busy clinicians, TR can be difficult to assess because several factors influence prognosis. A risk score helps by bringing key details together, such as symptoms, right-heart function, echocardiography findings, kidney and liver blood tests, blood pressure, and other health problems. Instead of looking at each factor separately, the score provides one practical estimate of risk. This makes it easier to explain the situation to patients, for example: “Your score suggests a lower chance of surviving the next year without further treatment.” It also supports triage, so high-risk patients can be referred earlier for advanced imaging, valve-team review, or intervention, while lower-risk patients can continue close monitoring. In this way, a simple score turns complex information into a clearer clinical decision.

From a healthcare-system perspective, a TR risk score can also improve how patients are managed. Hospitals can use it to identify patients who may benefit from a dedicated valve or right-heart program. Insurance providers and healthcare planners may use risk-based criteria to guide access to advanced treatments, including catheter-based repair when appropriate. Researchers can also use the score to group patients more accurately in clinical studies and test whether treatments work best in high-risk groups. Overall, a practical TR score can help move this often-overlooked valve disease toward a more organised, timely, and patient-centred approach to care.

Who It Affects

A lot of patients suffering from TR at a moderate or severe level can greatly gain from this technique. It will include patients suffering from left ventricular heart disease for many years with secondary involvement of their tricuspid valves along with patients with primary TR (as a result of leaflet damage, pacemaker leads, infectious endocarditis, and so on). All of these patients are usually older and have other medical problems including atrial fibrillation, pulmonary hypertension, renal failure, and others.

Clinicians at all levels will feel the difference too.General Practitioners are generally the first to encounter any problems such as increased fatigue, swelling of legs, and multiple hospitalizations due to heart failure. An easy to use risk score will help GPs refer patients before it reaches that point. There is also going to be use of the risk score by cardiologists and radiologists to direct further tests or actions needed. In one example, a patient with a high risk score gets an immediate echocardiogram done and is directed to the valve clinic whereas a low risk patient will only need to have follow up arranged.

Healthcare systems and payers have their own interest as well. Treatment of advanced TR, in most cases, involves costly ICU admission and complicated rehabilitation process. On the other hand, an intervention in early stages of TR in patients who pose low risk implies exposure to risks of procedure with no added value. With the use of effective scoring system, this trade-off becomes clearer. Payors will have the ability to determine which patients require expensive procedures in the current time and which should be able to wait. Hospitals and healthcare policy makers will be able to implement care pathways and quality measures (such as speed of assessing high-risk TR patients by specialist). Family members and caregivers will gain from reliable predictions as well. If the risk score of the patient is low, it will assure everyone, and if it is high, they will be aware of aggressive care required.

What Changes

• Practical risk stratification: With a risk score in hand, doctors and patients get a clear picture of danger. Instead of vague terms, clinicians can say “Your TR score is high, which means we should act now.” Patients see a concrete number or category, which motivates timely decisions. This clarity makes discussions smoother: a high score may lead to earlier surgery or catheter repair, while a low score leads to careful watch-and-wait. In either case, everyone knows the plan is based on objective information. In effect, the score becomes a new vital sign for TR – something as routine as blood pressure in guiding care.
• New expectations for clinicians:Cardiologists and primary care physicians will need to learn the score and talk about it routinely. That means explaining to patients, for instance, that an elevated score is driven by things like right-heart congestion and organ stress. It also means checking the score at each visit or hospitalization. Over time, clinics may include risk-score reports in discharge summaries or clinic notes. The goal is a shared language: instead of just saying “mild, moderate, severe TR,” we might say “low-risk” or “high-risk” TR based on the score. This changes how doctors communicate, turning a complex echo report into a straightforward guidance.
• Streamlined care for heart teams: Hospitals could form dedicated tricuspid valve teams or clinics, similar to heart failure programs. Patients with higher scores would be fast-tracked to these teams. Practically, this might mean sooner appointments for advanced imaging (MRI, CT, or echo) or expedited surgical evaluation. By prioritizing based on score, the system ensures the sickest patients get urgent attention while preventing bottlenecks. For example, in a busy hospital, a moderate-risk patient might wait in the general clinic line, whereas a high-risk patient gets a same-day slot with the valvular heart disease team.
• Policy ripple effects:The score could influence guidelines and coverage policies. For instance, some healthcare systems might require a certain risk level before approving new therapies. Advocacy groups and patient safety organizations might push for including the score in quality measures. Insurance companies could tie reimbursement to score thresholds, ensuring that interventions go to those most likely to benefit. Over time, the score could even become a national or international benchmark: if one hospital adopts it and shows better outcomes, others may follow suit. This can create a de facto standard of care for TR, even before formal guidelines catch up.
• Putting scores to work won’t be without caveats. No risk model is perfect – it’s a compromise between usefulness and simplicity. By design, the score uses just a handful of inputs to spit out a number. That makes it easy to use, but it also means nuance gets lost. For example, the score might not directly include frailty, subtle imaging findings, or a patient’s personal goals. Therefore clinicians must remember: the score is an aid, not a replacement for judgment. If a score-based calculator suggests a very high risk, doctors should still consider whether something unusual (like an advanced kidney disease) is skewing it. Likewise, a low score doesn’t mean ignore the patient’s complaints. The model should be validated in diverse populations, since a tool developed in one hospital or country might not work exactly the same elsewhere.
• On the ground, the score changes daily practice in straightforward ways. A primary care doctor could plug a patient’s vitals, lab results, and recent echo findings into an electronic calculator during a routine visit. If the score is high, the electronic health record can flag an automatic referral to a valve specialist or trigger scheduling an early echo. On the hospital floor, a high score at discharge might prompt scheduling a cardiology follow-up in a week or two. These small steps – like built-in alerts and checklists – help translate the score into action. Over time, teams may even train nurses or physician assistants to run the score for patients in clinic, so nothing falls through the cracks.
• Implementation challenges remain. Hospitals will need to build the score into electronic systems and make it easy to use. Clinicians who learned to prioritize left-heart issues will need education and reminders about the importance of TR. Insurance and billing rules might need updates too – to cover the extra imaging or specialist visits that a high score suggests. Equity is a critical concern: patients in rural or underserved areas may have trouble seeing a heart valve specialist quickly. Implementing the score must go hand-in-hand with efforts to expand access, such as telemedicine consultations or outreach clinics, so that high-risk patients in every community can get appropriate care.
• Looking ahead, the score’s importance will grow as new treatments emerge. Surgical repair or replacement of the tricuspid valve is lifesaving for some, but carries high risk in frail patients. New catheter-based repairs (similar to devices used for mitral regurgitation) are now available but not risk-free. With more options, timing becomes even more critical. The score helps answer the question, “When should we intervene?” For example, if a patient’s risk score becomes moderately high, the team might consider earlier transcatheter repair rather than waiting for emergency surgery. By quantifying the long-term danger, the score can shift practice toward doing a procedure at a safer point rather than waiting until it’s almost too late.
• Researchers and health systems will need to keep refining the score. This can involve prospective studies involving testing the scoring system in different patient populations. Researchers may wish to introduce additional variables such as blood markers or further echocardiographic measurements. AI and data obtained through the use of EHRs can allow for automatic identification of at-risk patients, but any such system will have to be thoroughly audited and free of bias. Finally, health care organizations will have to consider more than just survival, including quality of life, rehospitalization rates, and symptom relief, when evaluating the effectiveness of the scoring system.
• Clinicians should also be clear with patients about what the score means. . It is a probability, and nothing more. Physicians can say something like: “Your risk score is 8 out of 12, meaning that patients who were similarly situated have historically had roughly a 40% probability of survival within one year without any additional interventions.” They will then explain why intervening would raise this number. This is a way to establish proper patient expectations. It makes an abstract concept tangible.
• Tricuspid regurgitation has finally moved out of the shadows.A risk stratification algorithm can serve as a guide for identifying patients who should receive more intensive monitoring or sooner treatment based on their mortality risk. Just like any other instrument, it will work optimally when used with appropriate clinical judgment and access to specialized care. If implemented carefully, the scoring system can help bridge the gap between detection and proper management of TR. References Davidson LJ, Tang GHL, Ho EC, et al. The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association. Circulation. 2024;149:e1223-e1238. Available from: https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000001232 Tomasoni D, Oriecuia C, Adamo M, et al. Prevalence and prognostic role of untreated moderate-to-severe tricuspid regurgitation: a systematic review and meta-analysis. Eur J Heart Fail. 2026. Available from: https://pubmed.ncbi.nlm.nih.gov/42250245/ Hochstadt A, Maor E, Ghantous E, et al. A validated score to predict one-year and long-term mortality in patients with significant tricuspid regurgitation. Eur Heart J Open. 2022;2(6):oeac067. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9703580/ Fernández-Avilés C, Ruiz Ortiz M, Fernández Ruiz A, et al. Prognostic scores in patients with severe tricuspid regurgitation: An external validation study. Eur J Clin Invest. 2025;55(3):e14379. Available from: https://pubmed.ncbi.nlm.nih.gov/39797490/